The addition of LR-IL-22 to a therapy regimen that includes WAI, chemotherapy, and immunotherapy can facilitate a safe and effective protocol to reduce tumor burden, increase overall survival, and improve the quality of life of an ovarian cancer patient. This evidence concerns the gene IL22 and neoplasm.